ClinicalTrials.gg
Not yet recruitingNCT07167186AMBUMICUpdated Sep 11, 2025

Evaluation of a Multimodal Day Hospital for the Overall Management of Patients With Chronic Inflammatory Bowel Diseases (IBD)

An observational study in Inflammatory Bowel Disease (IBD), Crohn Disease and Ulcerative Colitis (Disorder), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 7 under way, 2 of them phase 3. Inflammatory Bowel Diseases · Assistance Publique - Hôpitaux de Paris.

Started
2025
with 1 other
Observational
6 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 13th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

5 of the 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Inflammatory bowel diseases (IBD) are long-term conditions affecting more than 250,000 people in France. They typically begin in young adults and are characterized by flare-ups interspersed with periods of remission. The impact of these diseases goes beyond digestive symptoms, with fatigue present in 50 to 80% of cases. The overall effect on health leads to a decline in quality of life and work productivity. Therapeutic management relies on long-term immunosuppressive treatments aimed at inducing prolonged remission. While therapeutic management has become more complex with an increasing number of available treatments, evaluating the effectiveness and tolerance of these treatments requires a multimodal approach, including therapeutic education and specific follow-up based on the patient's profile and treatment, with the goal of comprehensive care and precision medicine.

Recently, multimodal day hospitalizations have been developed, particularly in response to the recent evolution of treatment administration routes toward subcutaneous or oral forms. In 2022, the gastroenterology and nutrition department of Saint Antoine Hospital, which follows 3,500 patients with CIBD, created a multimodal day hospital (DH) (four interventions) dedicated to patients treated with biologics and Janus kinase inhibitors. In a single session, this approach systematically combines (1) specific biological tests, especially pharmacokinetics, (2) a consultation with a gastroenterologist, (3) a consultation with a therapeutic education nurse, (4) and, depending on the identified needs of the patients, a dietary workshop or fatigue management session; a specialized dermatology or rheumatology consultation; and an ultrasound of the intestinal wall.

The goal of this study is to assess the benefits of a multimodal day hospital on the management and skills of patients with IBD.

Read the detailed description

This is a non-interventional cohort study. Patients will be included over a 6-month period during a scheduled multimodal day hospital visit as part of their care. Before their day hospital appointment, patients will receive an information sheet explaining the research process.

M0 Inclusion:

Patients who agree to participate in the research will receive evaluation questionnaires to be completed online, which include:

  • Access to care,
  • Adherence according to the self-declared adherence rate,
  • Knowledge about their disease (IBDKID2),
  • Fatigue (FACIT-F),
  • Dietary questionnaire (SLFQ),
  • Productivity (WPAI). Patients who do not wish to participate in the study during their visit to the multimodal day hospital will be excluded from the study.

Day of DH:

Upon arrival at the multimodal day hospital, if the questionnaires have not been completed in advance, patients will be offered the opportunity to complete them during their visit, with an estimated duration of 30 minutes.

M1 (4 Weeks Post-DH):

Four weeks after the day hospital visit, patients will receive an email with a link to complete the questionnaires again (adherence, knowledge of their disease, fatigue, dietary questionnaire, and productivity). If the questionnaires are not completed, a reminder email will be sent 3 days and 1 month after the due date. If there is no response, a phone call will be scheduled 1 week after the initially planned date by the clinical research technician. Questionnaires can be filled out up to 8 weeks after inclusion.

M6 (6 Months Post-DH):

Six months after the day hospital visit, patients will again receive an email with a link to complete the questionnaires (adherence, knowledge of their disease, fatigue, dietary questionnaire, and productivity). A reminder email will be sent 3 days and 1 month after the due date if there is no response. If there is still no response, a phone call will be made 1 week after the initially scheduled date by the clinical research technician. Questionnaires can be completed up to 7 months after inclusion.

Between M0 and M1:

Treatment optimization and the update of the vaccination schedule will be recorded in the patient's electronic health record.

Study Participation End:

Participation in the study will conclude after the completion of the questionnaires, no later than 7 months after inclusion Statistical analysis The analysis will be performed using SAS v9.4 software (or a later version) by the URC-Est at the end of the study after the database freeze. A detailed statistical analysis plan will be written before the database freeze. A flow chart will be created.

The patient profile at inclusion will be described, including comorbidities, characteristics of the IBD (such as clinical and biological activity at the time of the day hospital visit), and treatments. The day hospital process will be evaluated, including the number of patients per session and the type of interventions performed.

Qualitative variables will be described by their frequency and count, while quantitative variables will be described by their mean and standard deviation or by their median and interquartile range, depending on their distribution.

Analysis of the Primary Endpoint The proportion of patients with an improvement in their skills at one month or an improvement in the management of their disease will be calculated. The proportion of patients with improvement in each of the two groups of criteria will also be calculated.

Analysis of Secondary Endpoints Secondary endpoints will be measured by the proportion of patients showing improvement for each individual item. The total number of items with improvement per patient will also be evaluated, as well as the proportion of patients with access to practitioners such as a dietitian specialized in IBD, a rheumatologist, or a dermatologist outside the day hospital, based on the dedicated questionnaire.

A logistic regression will be conducted to identify the predictors of improvement in patient skills or disease management, based on patient characteristics, IBD features, and treatments.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Crohn Disease
  • Ulcerative Colitis (Disorder)

Keywords

  • Therapeutic education
  • Inflammatory bowel disease
  • Crohn's disease
  • Ulcerative colitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ulcerative colitis and Crohn's disease for more than 3 months, with a confirmed diagnosis according to European guidelines, being followed in the gastroenterology department at Saint Antoine Hospital and eligible for a multimodal day hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient diagnosed with ulcerative colitis and Crohn's disease for more than 3 months, with a confirmed diagnosis according to European guidelines, being followed in the gastroenterology department at Saint Antoine Hospital.
  • Aged over 18 years.
  • Undergoing a multimodal day hospital visit, regardless of the scheduled intervention in the gastroenterology department at Saint Antoine Hospital.
  • Not opposed to participating in the research.

Exclusion criteria

Exclusion Criteria:

  • Protective measure in place.
  • Patient who has previously participated in an equivalent day hospital program.
  • Pregnant woman.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Proportion of patients with a change in their skills at one month or a modification in the management of their disease

    For this study, the benefit of the multimodal Day Hospital (DH) will be evaluated through two groups of criteria: * The criteria of the "Improvement of Patient Skills" group, assessed at the time of day hospitalization and one month later. * The criteria of the "Improvement in Patient Management" group, assessed at the time of day hospitalization. The multimodal DH will be considered beneficial if at least one of these two groups of criteria is met.

    Time frame: 1 month

Secondary outcomes

  1. self-declared drug adherence rate

    Evaluation of skill-related criteria at the 6-month mark self-declared drug adherence rate: scale from 0 to 100 A threshold below 80% defines non-compliant patients. A relative increase of 20% will be considered a significant improvement.

    Time frame: 1 and 6 month

  2. Percentage of patients requiring a treatment discontinuation

    Time frame: 1 and 6 month

  3. Percentage of patients requiring changes in treatment dosages

    Time frame: 1 and 6 month

  4. The proportion of patients showing improvement for each individual item.

    Time frame: 1 and 6 months

  5. The total number of improved criteria per patient.

    Time frame: 1 and 6 months

  6. The proportion of patients with access to practitioners such as a dietitian specialized in IBD, a rheumatologist, or a dermatologist, outside of the Day Hospital (DH)

    Time frame: 1 and 6 months

  7. IBD-KID2 score

    Understanding of disease and treatment based on the IBD-KID2 (inflammatory bowel disease knowledge inventory device) score, comprising 13 questions An absolute increase in score of 3 units will be considered a significant improvement

    Time frame: 1 and 6 month

  8. SLQF score for SLFQ Dietary Behavior Change

    Patients are categorized into four knowledge categories: insufficient, problematic, sufficient, or excellent, based on respective scores of 0-25, 25-33, 33-42, and 42-50. Any move to a higher category will be considered a significant improvement.

    Time frame: 1 and 6 month

  9. Change in fatigue behaviors assessed using the Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F)

    An absolute increase in score of 4 units will be considered a significant improvement

    Time frame: 1 and 6 month

  10. Work Productivity and Activity Impairment Questionnaire in Crohn's disease (WPAI:CD)

    Change in work effectiveness behaviors assessed by the Work Productivity and Activity Impairment Questionnaire in Crohn's disease (WPAI:CD) An absolute increase in score of 20 units will be considered a significant improvement.

    Time frame: 1 and 6 month

  11. Work Productivity and Activity Impairment Questionnaire in in Ulcerative Colitis (WPAI:UC)

    Change in work Productivity and Activity Impairment Questionnaire in Ulcerative Colitis (WPAI:UC) An absolute increase in score of 20 units will be considered a significant improvement.

    Time frame: 1 and 6 month

07

Study locations

1 site
  • Service de gastroentérologie Hôpital Saint Antoine
    Paris, 75012, France
08

References and documents

Individual participant data

Plan to share: No — The questionnaires will be completed directly by the patients using an electronic platform accessible via the Internet (e-CRF Cleanweb - Telemedicine SA, with the "ePro" feature), developed by URCEST in collaboration with the coordinating investigator. This method of data collection was chosen to facilitate the completion process and streamline the questionnaire flow. A report of anonymized aggregated data at the end of the study will be published. No individual participant data will be available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Feb 2026, 5 months later.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 5 months is below that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Sep 11, 2025
StartEst.
Sep 2025
Primary completionEst.
Feb 2026
CompletionEst.
Jul 2026
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07167186
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Sep 2025 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Paul Mclellan, Doctor
Contact
paul.mclellan@aphp.fr
00 33 149283161
Julien Kirchgesner, Doctor
Contact
julien.kirchgesner@aphp.fr
0033 149283162
Paul Mclellan, Doctor
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion